PT - JOURNAL ARTICLE AU - Kim, Sun AU - Can, Melike Hazal AU - Agizew, Tefera B. AU - Auld, Andrew F. AU - Balcells, Maria Elvira AU - Bjerrum, Stephanie AU - Dheda, Keertan AU - Dorman, Susan E. AU - Esmail, Aliasgar AU - Fielding, Katherine AU - Garcia-Basteiro, Alberto L. AU - Hanrahan, Colleen F. AU - Kebede, Wakjira AU - Kohli, Mikashmi AU - Luetkemeyer, Anne F. AU - Mita, Carol AU - Reeve, Byron W. P. AU - Silva, Denise Rossato AU - Sweeney, Sedona AU - Theron, Grant AU - Trajman, Anete AU - Vassall, Anna AU - Warren, Joshua L. AU - Yotebieng, Marcel AU - Cohen, Ted AU - Menzies, Nicolas A. TI - Factors associated with tuberculosis treatment initiation among bacteriologically negative individuals evaluated for tuberculosis: an individual patient data meta-analysis AID - 10.1101/2024.04.07.24305445 DP - 2024 Jan 01 TA - medRxiv PG - 2024.04.07.24305445 4099 - http://medrxiv.org/content/early/2024/04/08/2024.04.07.24305445.short 4100 - http://medrxiv.org/content/early/2024/04/08/2024.04.07.24305445.full AB - Background Globally, over one-third of pulmonary tuberculosis (TB) disease diagnoses are made based on clinical criteria after a negative diagnostic test result. Understanding factors associated with clinicians’ decisions to initiate treatment for individuals with negative test results is critical for predicting the potential impact of new diagnostics.Methods We performed a systematic review and individual patient data meta-analysis using studies conducted between January/2010 and December/2022 (PROSPERO: CRD42022287613). We included trials or cohort studies that enrolled individuals evaluated for TB in routine settings. In these studies participants were evaluated based on clinical examination and routinely-used diagnostics, and were followed for ≥1 week after the initial test result. We used hierarchical Bayesian logistic regression to identify factors associated with treatment initiation following a negative result on an initial bacteriological test (e.g., sputum smear microscopy, Xpert MTB/RIF).Findings Multiple factors were positively associated with treatment initiation: male sex [adjusted Odds Ratio (aOR) 1.61 (1.31–1.95)], history of prior TB [aOR 1.36 (1.06–1.73)], reported cough [aOR 4.62 (3.42–6.27)], reported night sweats [aOR 1.50 (1.21–1.90)], and having HIV infection but not on ART [aOR 1.68 (1.23–2.32)]. Treatment initiation was substantially less likely for individuals testing negative with Xpert [aOR 0.77 (0.62–0.96)] compared to smear microscopy and declined in more recent years.Interpretation Multiple factors influenced decisions to initiate TB treatment despite negative test results. Clinicians were substantially less likely to treat in the absence of a positive test result when using more sensitive, PCR-based diagnostics.Funding National Institutes of HealthEvidence before this study In countries with a high burden of tuberculosis, over one-third of notified cases for pulmonary TB are diagnosed based on clinical criteria, without bacteriological confirmation of disease (‘clinical diagnosis’). For these individuals with negative bacteriological test results, there is limited evidence on the factors associated with higher or lower rates of clinical diagnosis. In the context of individual clinical trials, some analyses have reported lower rates of treatment initiation for individuals testing negative on new cartridge-based PCR tests (e.g., Xpert MTB-RIF), as compared to individuals testing negative in sputum smear microscopy.Added value of this study This study conducted a systematic review of studies that collected data on patient characteristics and treatment initiation decisions for individuals receiving a negative bacteriological test result as part of initial evaluation for TB. Patient-level data from 13 countries across 12 studies (n=15121) were analyzed in an individual patient data meta-analysis, to describe factors associated with clinicians’ decisions to treat for TB disease. We identified significant associations between multiple clinical factors and the probability that a patient would be initiated on TB treatment, including sex, history of prior TB, reported symptoms (cough and night sweats), and HIV status. Controlling for other factors, patients testing negative on PCR-based diagnostics (e.g., Xpert MTB/RIF) were less likely to be initiated on treatment than those testing negative with smear microscopy.Implications of all the available evidence Rates of clinical diagnosis for TB differ systematically as a function of multiple clinical factors and are lower for patients who test negative with new PCR-based diagnostics compared to earlier smear-based methods. This evidence can be used to refine diagnostic algorithms and better understand the implications of introducing new diagnostic tests for TB.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022287613 Funding StatementResearch reported in this publication was supported by the National Institute of Allergy And Infectious Diseases of the National Institutes of Health under Award Number U01AI152084. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board of the Harvard School of Public Health gave ethical approval for this work (IRB21-1488).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.